Last reviewed 2026-04-20 · How we verify

HZ/su VACCINE (hz-su-vaccine)

Pfizer's HZ/su VACCINE is a marketed vaccine for adults 50+ to prevent herpes zoster (shingles). It has generated $63.6B in revenue. The vaccine has undergone 30 trials and 18 publications. Its mechanism is not specified on Wikipedia. This vaccine is a key product for Pfizer Inc. and has significant commercial importance. It is a crucial product in the pharma market.

At a glance

Approved indications

• Prevention of herpes zoster (shingles) in adults 50 years of age and older

Common side effects

No common side effects on file.

Drug interactions

• Live vaccines
• Immunosuppressive agents
• Interferon
• Corticosteroids
• Azathioprine
• Mycophenolate mofetil
• Sirolimus
• Tacrolimus
• Cyclosporine
• Methotrexate

Key clinical trials

• Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
• A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (PHASE1, PHASE2)
• Safety of the Herpes Zoster Subunit Vaccine in Lupus (PHASE4)
• A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults (PHASE3)
• Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (PHASE3)
• Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
• A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PHASE3)
• A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HZ/su VACCINE CI brief — competitive landscape report
• HZ/su VACCINE updates RSS · CI watch RSS
• Pfizer portfolio CI